Zealand: shares up after successful diabetes trial
(CercleFinance.com) - Zealand Pharma on Tuesday unveiled successful results for a Phase 3 trial with its experimental drug dasiglucagon for severe hypoglycemia in diabetes, news which sent its shares up over 8% today.
The Copenhagen-based biotech firm said that the Phase 3 trial confirmed that a single dose of dasiglucagon administered via a rescue pen rapidly increased blood glucose levels in patients with type 1 diabetes following hypoglycemia.
The primary result also demonstrates that the median time to blood glucose recovery was 10 minutes for dasiglucagon, which was better than placebo (35 minutes).
This is the third consecutive Phase 3 trial with positive results for dasiglucagon, Zealand said.
Zealand shares were up 8.8% at 142.5 Danish kronor in early-afternoon trading Tuesday on the OMX Nasdaq.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Copenhagen-based biotech firm said that the Phase 3 trial confirmed that a single dose of dasiglucagon administered via a rescue pen rapidly increased blood glucose levels in patients with type 1 diabetes following hypoglycemia.
The primary result also demonstrates that the median time to blood glucose recovery was 10 minutes for dasiglucagon, which was better than placebo (35 minutes).
This is the third consecutive Phase 3 trial with positive results for dasiglucagon, Zealand said.
Zealand shares were up 8.8% at 142.5 Danish kronor in early-afternoon trading Tuesday on the OMX Nasdaq.
Copyright (c) 2019 CercleFinance.com. All rights reserved.